CXCL9 and neoplasm: Together, it is possible that elevated baseline levels of plasma CXCL9, the presence of tumor-related NY-ESO-1 autoantibodies, and reduced plasma VEGFR2 highlight heavily pre-treated tumors that may exhibit primary resistance to treatment despite the presumed presence of immune infiltration and recognition.